IAMH
SMMT icon

IvyRock Asset Management (HK)’s Summit Therapeutics SMMT Stock Holding History

IvyRock Asset Management (HK)’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-91,741
Closed -$1.77M – 17
2025
Q1 		$1.77M Sell
91,741
-74,759
-45% -$1.5M 0.83% 7
2024
Q4 		$2.97M Buy
+166,500
New +$3.23M 1.31% 11

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

IvyRock Asset Management (HK)'s SMMT Position: Q2 2025 in Review

IvyRock Asset Management (HK) sold out of Summit Therapeutics (SMMT) in Q2 2025, closing a stake of 91,741 shares — an estimated $1.77M sold.

IvyRock Asset Management (HK) first reported a position in SMMT in Q4 2024 and held it in 2 quarters. The position peaked at $2.97M in Q4 2024. 238 funds tracked by Wall St. Rank hold SMMT as of Q2 2025.

  • IvyRock Asset Management (HK) reported no remaining Summit Therapeutics position as of Q2 2025 after selling out during the quarter.
  • IvyRock Asset Management (HK) sold 91,741 Summit Therapeutics shares in Q2 2025, an estimated $1.77M.
  • IvyRock Asset Management (HK) first reported a position in Summit Therapeutics in Q4 2024 and held it in 2 quarters.
  • IvyRock Asset Management (HK)'s Summit Therapeutics position peaked at $2.97M in Q4 2024.
  • 238 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2025.

Based on IvyRock Asset Management (HK)'s 13F filing for Q2 2025, filed 12 Aug 2025.